VIZIMPRO Home indication

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) include dacomitinib (VIZIMPRO) as a Category 1 treatment option for first-line therapy in patients with sensitizing EGFR-positive, metastatic NSCLC.1
 
NCCN=National Comprehensive Cancer Network® (NCCN®).
REFERENCE
1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.2.2019. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed November 21, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.